Skip to content
Cyclodextrin News

Cyclodextrin News

A forum for researchers, students and applicants in the field of cyclodextrin technology

  • Home
  • Pharma applications
  • Non-pharma applications
  • CD derivatives
  • Events
  • E-ducation

Tag: autophagy

February 21, 2023 CD as API / Pharma applications

Parkinson’s Disease Phenotypes in Patient Neuronal Cultures and Brain Organoids Improved by 2-Hydroxypropyl-β-Cyclodextrin Treatment

Parkinson-disease-patient-derived cells presented differences in their energetic profile, imbalanced proliferation, apoptosis, mitophagy, and a reduced differentiation efficiency to tyrosine hydroxylase

Continue reading

February 3, 2023 CD as API / CD derivatives / Pharma applications

Mannose-modified methyl-β-cyclodextrin suppresses tumor growth

Methylated β-cyclodextrin (MeβCD) can extract cholesterol from lipid rafts and induce apoptosis in cancer cells by inhibiting activation of the

Continue reading

July 28, 2022 Drug delivery / Pharma applications

Cellular Effects of Cyclodextrins: Studies on Caco-2 and HeLa Cells

In this work the cellular internalization and the intracellular effects of (2-hydroxypropyl)-beta (HPBCD) and random methyl-beta cyclodextrin (RAMEB) on Caco-2

Continue reading

March 12, 2022 Drug delivery

Cancer-Related Intracellular Signalling Pathways Activated by Doxorubicin/Cyclodextrin-Graphene-Based Nanomaterials

In the last decade, nanotechnological progress has generated new opportunities to improve the safety and efficacy of conventional anticancer therapies.

Continue reading

February 23, 2022 CD as API / Pharma applications

HPBCD for Treatment of Parkinson Disease

The recent work of Jarazo et al. demonstrates that HP-β-CD ameliorates the dopaminergic neuronal loss phenotype, confirming the therapeutic potential

Continue reading

November 23, 2021 CD as API / Pharma applications

Folate-appended CDs in cancer therapy

The team of Motoyama in Kumamoto has recently published new results on folate-appended CDs in leukemia and ovarian cancer (1,2).

Continue reading

November 22, 2021 Uncategorized

Use of cyclodextrins in diseases and disorders involving phospholipid dysregulation

A patent application by Knut M. Wittkowski (ASDERA LLC, US) entitled “Use of cyclodextrins in diseases and disorders involving phospholipid

Continue reading

October 21, 2021 CD as API / Pharma applications

Parkinson’s Disease Phenotypes in Patient Neuronal Cultures and Brain Organoids Improved by 2-Hydroxypropyl-β-Cyclodextrin Treatment

OrganoTherapeutics in collaboration with University of Luxemburg has published interestingin vitro and in vivo results on the effects of HPBCD

Continue reading

February 4, 2021 CD as API / Drug delivery / Events

Press Release – Development of Autophagy Inducing Cyclodextrin Derivatives for Aging-associated Diseases

CycloLab Cyclodextrin R&D Ltd. proudly announces winning of a national grant about the development of cyclodextrin-dervatives for autophagy-associated neurodegenerative diseases.

Continue reading

October 5, 2020 CD as API / Pharma applications

An antibody–supermolecule conjugate for cancer chemotherapy

In this study, antibody–supermolecule conjugates, consisting of a tumor-specific antibody and acid-labile polyrotaxane containing methylated b-cyclodextrin (Me-PRX), were designed to

Continue reading

Posts navigation

1 2 Next Posts»

Recent Posts

  • Continuous flow synthesis of 6-monoamino-6-monodeoxy-β-cyclodextrin
  • Synergistic Antitumor Potency of a Self-Assembling Cyclodextrin Nanoplex for the Co-Delivery of 5-Fluorouracil and Interleukin-2 in the Treatment of Colorectal Cancer
  • Oculis goes public on the Nasdaq Stock Market
  • Special Issue “Drug Carriers Production Processes for Innovative Human Applications”
  • Anomalous Properties of Cyclodextrins and Their Complexes in Aqueous Solutions

Tags

alpha-CD antiviral Biotechnology Cancer therapy Captisol Cholesterol Clinical trial conference coronavirus Covid-19 cyclodextrin polymer Dexolve drug delivery drug delivery systems FDA Food Gilead History HPBCD Nanoparticles nanotechnology Niemann Pick Disease RAMEB remdesivir SBECD Special issue Sugammadex Synthesis wastewater treatment

Follow Us

  • LinkedIn
  • Twitter
  • Facebook

Categories

  • Agriculture (13)
  • Analysis (35)
  • CD as API (206)
  • CD derivatives (258)
  • Cosmetics and toilettry (21)
  • Drug delivery (440)
  • E-ducation (55)
  • Environmental (77)
  • Events (160)
  • Food (124)
  • Gene delivery (10)
  • In Hungarian (4)
  • Life sciences (15)
  • Non-pharma applications (215)
  • Other industrial use (59)
  • Pharma applications (705)
  • Supramolecular systems (25)
  • Uncategorized (43)

Top Posts

  • Synergistic Antitumor Potency of a Self-Assembling Cyclodextrin Nanoplex for the Co-Delivery of 5-Fluorouracil and Interleukin-2 in the Treatment of Colorectal Cancer
  • Lanosterol eye drops for cataract treatment
  • Practical Considerations about the Cyclodextrin Solubilities – A Quickstart Guide for Newbies
  • Continuous flow synthesis of 6-monoamino-6-monodeoxy-β-cyclodextrin
  • How air fresheners work?
  • International Conference on Bioinspiration and Biobased​ Materials
  • Mallinckrodt gave up further development of adrabetadex (VTS-270; HPBCD)
  • Australian company pioneering Cavadextrin for regression of atherosclerosis
  • Antidote-like effect of SBECD of plant neurotoxin veratridine on neuro-2a cell viability
  • Website of EuroCD Conference is open

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 523 other subscribers
 

Loading Comments...